日光性角化病的现行与新型预防治疗选择
日光性角化病(AK)多见于I/II型皮肤或具有特定遗传因素且长期暴露于紫外线的人群,被视为原位鳞状细胞癌(SCC)的前驱病变,但无法预测哪些AK病灶会进展为SCC,因此推荐早期治疗。本文更新AK相关关键信息,并综述现行及新型治疗选择,包括局部病灶导向或区域导向治疗及其联合方案,以及口服烟酰胺在高危患者中显著降低新发非黑素瘤皮肤癌(NMSC)和AK发生率的作用。
要点
- AK多见于I/II型皮肤或特定遗传因素且长期紫外线暴露者,推荐早期治疗。
- AK被视为原位SCC前驱病变,但无法预测哪些病灶会进展为SCC。
- 口服烟酰胺可显著降低高危患者新发NMSC和AK的发生率。
核心结论
- AK推荐早期治疗,现行治疗包括多种局部病灶导向或区域导向治疗及其联合方案。
- 口服烟酰胺在高危患者中可显著降低新发NMSC和AK的发生率。
研究设计与样本
- 本文为综述,旨在更新AK最相关信息并综述现行及新型治疗选择。
主要发现
- AK主要发生于I型和II型皮肤或具有特定遗传因素且长期暴露于紫外线的人群。
- AK可被视为原位SCC的前驱病变,属于非黑素瘤皮肤癌(NMSC)的一种。
- 目前仍无法预测哪些AK病灶会进展为SCC。
- 尽管进展为SCC的AK患者增多,但目前仍无明确的AK治疗策略建议。
- 口服烟酰胺在高危患者中显著降低新发NMSC和AK的发生率。
临床怎么用
- 对AK病灶推荐早期治疗,可选局部病灶导向或区域导向治疗或两者联合。
- 在高危患者中可考虑口服烟酰胺以降低新发NMSC和AK的发生率。
局限性
- 目前仍无法预测哪些AK病灶会进展为SCC。
- 目前仍无明确的AK治疗策略建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Actinic keratosis (AK) is a characteristic skin lesion on skin areas of subjects with mainly phototype I and phototype II, or with specific genetic factors and who are exposed to prolonged ultraviolet radiation. AK may be considered a precursor of in situ squamous cell carcinoma (SCC), a type of non-melanoma skin cancer (NMSC). However, it is still not possible to predict which AK lesions will develop into SCC. Early treatment of AK is therefore recommended. Despite the increasing number of patients with AK developing into SCC, to date, there is still no clear suggestion of therapeutic strategy for AK. Current treatment consists of a multitude of topical lesion-directed or field-directed therapies or a combination of both. Recently, orally administered nicotinamide has shown to significantly reduce rates of new NMSC and AK in high-risk patients. This study aims to provide an update on the most relevant information about AK and to provide an insight into current and new treatment options.
引用
- Arenberger P, Arenbergerova M. New and current preventive treatment options in actinic keratosis. J Eur Acad Dermatol Venereol. 2017. PMID: 28805940. doi:10.1111/jdv.14375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。